Ultime notizie per Addus HomeCare (NASDAQ:ADUS) Azioni

ADDUS HOMECARE CORP

Addus HomeCare

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.

Addus HomeCare Corporation - Common Stock

Addus HomeCare Corp

Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.33 by 6.77 percent. This is a 17.36 percent increase over earnings of $1.21 per share from the same period last year. The company reported quarterly sales of $337.71 million which missed the analyst consensus estimate of $339.88 million by 0.64 percent. This is a 20.29 percent increase over sales of $280.75 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

ADUS

Addus HomeCare Q1 Adj. EPS $1.42 Beats $1.33 Estimate, Sales $337.71M Miss $339.88M Estimate

ACEL

ADEA

AESI

AMRC

AOMR

AORT

ARES

AROC

AXSM

BCRX

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CORT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

HSTM

IART

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NBIX

NGVT

NMFC

NSSC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

JMP Securities analyst Nicholas Jones reiterates Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Market Outperform and maintains $150 price target.

Price Target

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Outperform on Addus HomeCare, Maintains $150 Price Target

5 analysts have shared their evaluations of Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $142.6, a high estimate of $150.00, and a low estimate of $129.00. Observing a downward trend, the current average is 0.83% lower than the prior average price target of $143.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322469_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Addus HomeCare is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Constantine Davides &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $150.00&#x7C;$150.00 &#x7C; 
&#x7C;Scott Fidel &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $142.00&#x7C;$142.00 &#x7C; 
&#x7C;Tao Qiu &#x7C;Macquarie &#x7C;Maintains &#x7C;Outperform &#x7C; $129.00&#x7C;$129.00 &#x7C; 
&#x7C;Raj Kumar &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Overweight &#x7C; $142.00&#x7C;$153.00 &#x7C; 
&#x7C;Ari Wald &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $150.00&#x7C;$145.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Addus HomeCare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Addus HomeCare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Addus HomeCare analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Addus HomeCare</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>A Deep Dive into Addus HomeCare's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Addus HomeCare's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 7.52%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Addus HomeCare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Addus HomeCare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.04%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Addus HomeCare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.52%, the company showcases efficient use of assets and strong financial health.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.28, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Addus HomeCare Stock

JMP Securities analyst Constantine Davides maintains Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Market Outperform and maintains $150 price target.

JMP Securities Maintains Market Outperform on Addus HomeCare, Maintains $150 Price Target

Stephens &amp; Co. analyst Scott Fidel reiterates Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Overweight and maintains $142 price target.

Stephens & Co. Reiterates Overweight on Addus HomeCare, Maintains $142 Price Target

Addus HomeCare Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), a provider of home care services, announced today that W. Bradley Bickham, the Company's President and Chief Operating Officer, will retire in March 2026.
Commenting on the announcement, Dirk Allison, Chairman and Chief Executive Officer of Addus, stated, "We are fortunate to have had Brad's steady leadership throughout our company's growth and expansion over the last eight years. I am grateful that he has agreed to continue in that capacity for another year, while also providing us with the time to identify and develop the next generation of our leadership. While all of us at Addus will miss working with Brad, I will particularly miss him as we have worked together since 2006. However, we are very happy for Brad and his family and wish him all the best in his retirement."

Management

Addus HomeCare Announces W. Bradley Bickham, The Company's President And Chief Operating Officer, Will Retire In March 2026.

4 analysts have shared their evaluations of Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Addus HomeCare, revealing an average target of $142.75, a high estimate of $150.00, and a low estimate of $129.00. This current average reflects an increase of 0.3% from the previous average price target of $142.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1740686430_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Addus HomeCare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$129.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Raj Kumar</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Ari Wald</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Addus HomeCare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Addus HomeCare's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Addus HomeCare analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Addus HomeCare</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Understanding the Numbers: Addus HomeCare's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Addus HomeCare's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.52%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Addus HomeCare's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.57% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Addus HomeCare's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.04%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.52%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.28, Addus HomeCare adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Addus HomeCare's Future

Stephens &amp; Co. analyst Raj Kumar maintains Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Overweight and lowers the price target from $153 to $142.

Stephens & Co. Maintains Overweight on Addus HomeCare, Lowers Price Target to $142

WIIM

Addus HomeCare shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS estimate.

Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) reported quarterly earnings of $1.07 per share which missed the analyst consensus estimate of $1.35 by 20.74 percent. This is a 18.94 percent decrease over earnings of $1.32 per share from the same period last year. The company reported quarterly sales of $297.100 million which beat the analyst consensus estimate of $291.526 million by 1.91 percent. This is a 7.51 percent increase over sales of $276.351 million the same period last year.

Addus HomeCare Q4 2024 Adj. EPS $1.07 Misses $1.35 Estimate, Sales $297.100M Beat $291.526M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Kosmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $416.02 million. 
• Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $110.85 million. 
• Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) is projected to report earnings for its fourth quarter. 
• Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $645.84 million. 
• BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) is expected to report quarterly loss at $0.06 per share on revenue of $127.72 million. 
• Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) is expected to report quarterly earnings at $4.95 per share on revenue of $1.48 billion. 
• Gran Tierra Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GTE#AMEX">GTE</a>) is projected to report earnings for its fourth quarter. 
• Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $1.08 billion. 
• Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) is estimated to report quarterly earnings at $1.18 per share on revenue of $2.96 billion. 
• Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) is likely to report quarterly earnings at $2.90 per share on revenue of $2.77 billion. 
• Fresh Del Monte Produce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $1.03 billion. 
• Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is estimated to report quarterly earnings at $3.35 per share on revenue of $1.52 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $6.46 million. 
• Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $1.01 billion. 
<h3>Companies Reporting After The Bell</h3>
• DMC Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) is likely to report quarterly loss at $0.29 per share on revenue of $140.50 million. 
• Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $559.19 million. 
• Clean Energy Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $99.87 million. 
• Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $78.20 million. 
• Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $159.89 million. 
• Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $281.61 million. 
• Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $469.68 million. 
• Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) is likely to report quarterly loss at $0.75 per share on revenue of $331.06 million. 
• Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $1.39 billion. 
• Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $91.03 million. 
• Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) is likely to report quarterly loss at $0.27 per share on revenue of $130.25 million. 
• BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) is likely to report quarterly earnings at $0.81 per share on revenue of $720.47 million. 
• SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is projected to report quarterly earnings at $2.22 per share on revenue of $684.39 million. 
• ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $6.77 billion. 
• Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $142.03 million. 
• Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $101.15 million. 
• EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $133.83 million. 
• Cannae Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNNE#NYSE">CNNE</a>) is projected to report quarterly loss at $0.29 per share on revenue of $105.90 million. 
• Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $116.68 million. 
• Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $1.59 billion. 
• Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) is estimated to report quarterly earnings at $1.06 per share on revenue of $1.35 billion. 
• Trip.com Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) is likely to report quarterly earnings at $0.54 per share on revenue of $1.69 billion. 
• HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $73.55 million. 
• Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $213.34 million. 
• Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $326.77 million. 
• Topgolf Callaway Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) is likely to report quarterly loss at $0.19 per share on revenue of $885.10 million. 
• Haverty Furniture Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $182.09 million. 
• JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $488.74 million. 
• ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $274.56 million. 
• Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) is estimated to report quarterly loss at $1.09 per share on revenue of $58.34 million. 
• Quaker Houghton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>) is projected to report quarterly earnings at $1.61 per share on revenue of $441.87 million. 
• Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIV#NYSE">AIV</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $53.10 million. 
• Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) is projected to report quarterly loss at $0.06 per share on revenue of $19.03 million. 
• Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) is projected to report quarterly loss at $0.15 per share on revenue of $200.55 million. 
• Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) is expected to report quarterly earnings at $1.35 per share on revenue of $278.36 million. 
• Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) is estimated to report quarterly earnings at $0.36 per share on revenue of $175.99 million. 
• Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) is likely to report quarterly earnings at $2.63 per share on revenue of $424.40 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report earnings for its fourth quarter. 
• Black Stone Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSM#NYSE">BSM</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $114.99 million. 
• LTC Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) is likely to report quarterly earnings at $0.65 per share on revenue of $42.81 million. 
• Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $1.19 billion. 
• Douglas Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLOW#NYSE">PLOW</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $155.23 million. 
• MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $289.38 million. 
• SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) is projected to report quarterly loss at $0.14 per share on revenue of $46.89 million. 
• Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $83.69 million. 
• Tortoise Capital Series Trust Tortoise Power and Energy Infrastructure Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPZ#NYSE">TPZ</a>) is expected to report earnings for its fourth quarter. 
• Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) is likely to report quarterly loss at $0.48 per share on revenue of $174.58 million. 
• Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $311.66 million. 
• Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) is projected to report quarterly earnings at $4.22 per share on revenue of $1.18 billion. 
• Clearway Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEN#NYSE">CWEN</a>) is expected to report earnings for its fourth quarter. 
• V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) is projected to report quarterly earnings at $1.15 per share on revenue of $1.10 billion. 
• Veris Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRE#NYSE">VRE</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $66.81 million. 
• GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $1.98 billion. 
• Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) is projected to report quarterly earnings at $0.19 per share on revenue of $171.47 million. 
• Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) is estimated to report quarterly earnings at $1.88 per share on revenue of $1.29 billion. 
• Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) is expected to report quarterly loss at $0.44 per share on revenue of $4.54 billion. 
• Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $43.47 million. 
• KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $2.00 billion. 
• Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $220.06 million. 
• Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) is likely to report quarterly earnings at $3.58 per share on revenue of $3.51 billion. 
• Apple Hospitality REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLE#NYSE">APLE</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $324.82 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLE

AZUL

BOOM

BRDG

BYON

CHGG

CIVI

CLNE

CNNE

CRGO

CWEN

FARO

GSHD

HLIO

ISPO

KSPI

LINC

MODG

MYGN

NTST

RIOT

SBAC

SIBN

SMMT

TCOM

TREX

UCTT

VCYT

VNOM

WLKP

Earnings Scheduled For February 24, 2025

Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $142.67, along with a high estimate of $150.00 and a low estimate of $136.00. This upward trend is apparent, with the current average reflecting a 1.33% increase from the previous average price target of $140.80.
<img src="https://www.benzinga.com/files/images/story/2025/1737748878_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Addus HomeCare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ari Wald</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$136.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$136.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Addus HomeCare's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Addus HomeCare's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Addus HomeCare analyst ratings.</a>
<h2>Delving into Addus HomeCare's Background</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Understanding the Numbers: Addus HomeCare's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Addus HomeCare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.04% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Addus HomeCare's net margin excels beyond industry benchmarks, reaching 6.96%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Addus HomeCare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.16%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Addus HomeCare's ROA excels beyond industry benchmarks, reaching 1.78%. This signifies efficient management of assets and strong financial health.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Addus HomeCare Stock: Analyst Perspectives (6 Ratings)

Oppenheimer analyst Ari Wald maintains Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Outperform and raises the price target from $145 to $150.

Oppenheimer Maintains Outperform on Addus HomeCare, Raises Price Target to $150

Addus HomeCare shares are trading higher. JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $150.

JMP Securities initiated coverage on Addus HomeCare Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), a provider of home-based personal care and clinical services.
JMP analysts see Addus HomeCare as having a uniquely strong and well-established presence in personal care services across multiple states, thanks to the company's scale and experienced management team.
The analyst writes that personal care is a cost-effective way to provide home-based services, especially as the U.S. faces a shortage of expensive skilled clinicians.
This approach also helps delay the need for more costly care options. With the highly fragmented personal care sector, Addus has opportunities to expand by adding complementary home health and hospice services to its existing markets.
The analysts expect this strategy to support sustained double-digit revenue growth for the company in the coming years.
In the third quarter, Addus HomeCare revenues were $289.8 million for the third quarter of 2024, a 7.0% increase compared with $270.7 million for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41727154/addus-homecare-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">the third quarter of 2023</a>.
JMP has initiated with a price target of $150, with <a target="_blank" href="https://www.benzinga.com/quote/ADUS/analyst-ratings" rel="noreferrer noopener">a Market Perform rating</a>.
Addus HomeCare recently acquired Gentiva's PC operations. The deal, the largest acquisition in the company's history, is expected to allow Addus HomeCare to enter Texas with critical mass and add personal care services in six other states, three of which are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42276478/addus-homecare-completes-acquisition-of-personal-care-operations-of-gentiva" rel="noreferrer noopener">new to the company</a>.
Gentiva's PC platform is expected to contribute annual revenue of $275 million-$280 million, prompting 29% year-over-year personal care growth for Addus HomeCare in 2025, above the segment's five-year CAGR (2019-2024E) of 8%.
JMP writes that in recent years, Addus HomeCare has expanded into value-based care (VBC) arrangements in select markets through its "Care Advantage" program.
The company is well-positioned to grow in this area thanks to its combination of clinical and non-clinical care resources, along with its large-scale operations and robust case management systems.
Price Action: ADUS stock is up 5.14% at $131.42 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/24/12/42505835/honeywell-advances-strategic-review-explores-aerospace-business-separation" target="_blank" rel="noreferrer noopener">Honeywell Advances Strategic Review, Explores Aerospace Business Separation</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Health Care

Initiation

Movers

Trading Ideas

General

As US Faces Shortage Of Expensive Skilled Clinicians, Home-Based Health Service Provider Addus HomeCare Is Well-Positioned To Grow: Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Eric Sheridan initiated coverage on Grindr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Buy rating and announced a price target of $20. Grindr shares closed at $15.74 on Friday. See how other analysts view this stock.</li>
<li>JMP Securities analyst Constantine Davides initiated coverage on Addus HomeCare Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Market Outperform rating and announced a price target of $150. Addus HomeCare shares closed at $125.00 on Friday. <a href="https://www.benzinga.com/quote/ADUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Matthew Caufield initiated coverage on Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) with a Buy rating and announced a price target of $30. Zenas BioPharma shares closed at $8.92 on Friday. <a href="https://www.benzinga.com/quote/ZBIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Constantine Davides initiated coverage on U.S. Physical Therapy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Market Outperform rating and announced a price target of $113. US Physical Therapy shares closed at $93.46 on Friday. See how other analysts view this stock.</li>
<li>Jones Trading analyst Justin Walsh initiated coverage on Alto Neuroscience, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) with a Buy rating and announced a price target of $18. Alto Neuroscience shares closed at $3.83 on Friday. <a href="https://www.benzinga.com/quote/ANRO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADUS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-1024x628.png" alt="" class="wp-image-693734" style="width:595px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-768x471.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields

Pre-Market Outlook

Markets

ANRO

GRND

USPH

ZBIO

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

JMP Securities analyst Constantine Davides initiates coverage on Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Market Outperform rating and announces Price Target of $150.

JMP Securities Initiates Coverage On Addus HomeCare with Market Outperform Rating, Announces Price Target of $150

RBC Capital analyst Ben Hendrix reiterates Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Outperform and maintains $136 price target.

RBC Capital Reiterates Outperform on Addus HomeCare, Maintains $136 Price Target

Stephens &amp; Co. analyst Scott Fidel maintains Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Overweight and raises the price target from $143 to $145.

Stephens & Co. Maintains Overweight on Addus HomeCare, Raises Price Target to $145

Press Releases

Addus HomeCare to Participate in Stephens Annual Investment Conference

Addus HomeCare Completes Acquisition of Personal Care Operations of Gentiva

Addus HomeCare Announces Fourth Quarter and Year-end 2024 Earnings Release and Conference Call

Addus HomeCare Announces Fourth Quarter and Year End 2024 Financial Results

Addus HomeCare to Participate in TD Cowen 45th Annual Health Care Conference

Addus HomeCare to Participate in March Investor Conferences

Addus HomeCare Announces Planned Retirement of Brad Bickham

Addus HomeCare Announces First Quarter 2025 Earnings Release and Conference Call

Addus HomeCare Announces First Quarter 2025 Financial Results

Addus HomeCare to Participate in Upcoming Investor Conferences in May

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Addus HomeCare

Notizie

Ultime notizie per Addus HomeCare (NASDAQ:ADUS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO